IP Library Granted Patent US 8,703,820
Granted Patent B2
US 8,703,820 · App. 12/902,972 · Granted Apr 22, 2014

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Inventors: Michael Graeber (Lawrenceville, NJ); Janusz Czernielewski (Biot, FR)
Assignee: Galderma Research & Development
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,820
App. No.
12/902,972
Granted
Apr 22, 2014
Kind
B2
Abstract

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Claims (20)

1. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting an individual's skin, said individual being in need of such treatment, comprising topically administering to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream.

2. The method according to claim 1 , wherein said individual is afflicted with common acne.

3. The method according to claim 2 , wherein the common acne is of moderate to moderately severe intensity.

4. The method according to claim 1 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

5. The method according to claim 2 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

6. A regime or regimen for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting an individual's skin, said individual being in need of such treatment, comprising topically administering to such individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor.

7. The regime or regimen according to claim 6 , wherein said individual is afflicted with common acne.

8. The regime or regimen according to claim 7 , wherein the common acne is of moderate to moderately severe intensity.

9. The regime or regimen according to claim 6 , wherein the composition comprises a gel.

10. The regime or regimen according to claim 7 , wherein the composition comprises a gel.

11. The regime or regimen according to claim 8 , wherein the composition comprises a gel.

12. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting an individual's skin, said individual being in need of such treatment, comprising topically administering to said individual an anti-acne effective amount of a pharmaceutical composition which comprises: (a) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof; (b) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate and methyl glucose sesquistearate: (c) water; and, (d) optionally, one or more additives selected from the group consisting of wetting agents, pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and UV-B screening agents and antioxidants; said composition being a gel or a cream.

13. The method according to claim 12 , wherein said individual is afflicted with common acne.

14. The method according to claim 13 , wherein the common acne is of moderate to moderately severe intensity.

15. A regime or regimen for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting an individual's skin, said individual being in need of such treatment, comprising topically administering to such individual an anti-acne effective amount of a pharmaceutical composition which comprises: 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof; one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate, water, alcohol and polyethylene glycol; and optionally, one or more additives selected from the group consisting of wetting agents, flavor enhancers, preservatives, stabilizers, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and UV-B screening agents and antioxidants.

16. The regime or regimen according to claim 15 , wherein said individual is afflicted with common acne.

17. The regime or regimen according to claim 16 , wherein the common acne is of moderate to moderately severe intensity.

18. The regime or regimen according to claim 15 , wherein the composition is a gel.

19. The regime or regimen according to claim 16 , wherein the composition is a gel.

20. The regime or regimen according to claim 17 , wherein the composition is a gel.

Priority Claims (1)
FR 02 03070 · Mar 12, 2002 · national
Continuity (5)
Continuation 12437008 · May 7, 2009
Continuation 10937612 · Sep 10, 2004
Continuation PCTEP0303246 · Mar 12, 2003
Provisional Application 60370223 · Apr 8, 2002
Related Publication 20110027204A1 · Feb 3, 2011